Big Data in Oncology Spotlight
This week’s big data in oncology spotlight: NCCN releases guidance to help physicians and patients determine the value of drugs, Mitra Biotech’s move to India pays off, and The Economist explores the impact startups are having on what it means to own a company.
NCCN is releasing a set of supplemental guidelines that “will provide patients with guidance about the cost of drugs used in their treatment, helping address a concern for many people undergoing a major medical event — what the financial repercussions of their condition are.”
Mitra Biotech, a cancer drug testing company co-founded by professors from Harvard and MIT, moved to India to maximize its ability to do personalized medicine; “six years later they’ve got a billion dollar valuation propelling them forward.”
When we think of how a company is run, we may have a specific picture in our minds. But the many successful startups in the United States are reinventing what a successful company looks like: “The most distinctive aspect of America’s vibrant startup sector is the way the ownership of companies is structured” — namely, contracts.
As telemedicine grows and spreads, more is being learned about its benefits. A recent study of over 800 patients with either congestive heart failure or COPD found a “65 percent reduction in number of hospital admissions, 72 percent reduction in number of Emergency Room visits, and 95 percent reduction in number of walk-in clinic visits.”
The articles above are from our dedicated Big Data in Oncology e-magazine. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)